StoxTorrent Pharmaceuticals vs Laurus Labs: share price & financials comparison
NSE: TORNTPHARM vs LAURUSLABS · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Torrent Pharmaceuticals vs Laurus Labs at a glance
Torrent Pharmaceuticals (TORNTPHARM) has a market capitalisation of ₹1,80,671 Cr, against ₹1,26,430 Cr for Laurus Labs (LAURUSLABS). Over the past year Laurus Labs has returned +143.3%, compared with +32.0% for Torrent Pharmaceuticals. On valuation, Torrent Pharmaceuticals trades at a lower P/E of 85.1 versus 94.4. Laurus Labs earns a higher return on equity (22.1% vs 11.6%). Torrent Pharmaceuticals comes out ahead on size, valuation and growth. Laurus Labs comes out ahead on profitability, financial health, momentum and technicals. Across the scored metrics below, Torrent Pharmaceuticals leads on 7 and Laurus Labs on 10. On StoxGud's 10-point checklist, Torrent Pharmaceuticals scores 7/10 and Laurus Labs scores 8/10.
| Metric | Torrent Pharmaceuticals | Laurus Labs |
|---|---|---|
| Size | ||
| Market cap | ₹1,80,671 Cr | ₹1,26,430 Cr |
| Revenue (latest FY) | ₹13,980 Cr | ₹6,813 Cr |
| Net profit (latest FY) | ₹2,163 Cr | ₹889 Cr |
| Valuation | ||
| P/E | 85.1 | 94.4 |
| P/B | 9.83 | 20.86 |
| Dividend yield | 0.71% | 0.07% |
| Profitability | ||
| Return on equity | 11.6% | 22.1% |
| Net profit margin | 12.2% | 17.1% |
| Operating margin | 33.2% | 30.4% |
| Growth | ||
| Revenue growth (YoY) | +50.8% | +33.4% |
| Net profit growth (YoY) | -9.6% | +126.4% |
| Revenue CAGR (multi-year) | +11.8% | +7.2% |
| Financial health | ||
| Debt to equity | 0.76 | 0.41 |
| Momentum | ||
| 1-month return | +0.7% | +14.0% |
| 1-year return | +32.0% | +143.3% |
| 3-year CAGR | +34.2% | +84.5% |
| 5-year CAGR | +26.8% | +36.4% |
| 10-year CAGR | +21.7% | — |
| Distance from 52W high | -7.3% | -2.7% |
| Technicals | ||
| RSI (14) | 66 | 71 |
| Price vs 200-day avg | +4.9% | +58.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Torrent Pharmaceuticals | Laurus Labs |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 7/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Torrent Pharmaceuticals or Laurus Labs?
Torrent Pharmaceuticals has a market cap of ₹1,80,671 Cr and Laurus Labs has a market cap of ₹1,26,430 Cr as of 06 Nov 2026.
Which has a lower P/E, Torrent Pharmaceuticals or Laurus Labs?
Torrent Pharmaceuticals has the lower P/E: Torrent Pharmaceuticals trades at 85.1 and Laurus Labs at 94.4.
Which gave better returns in the last year, Torrent Pharmaceuticals or Laurus Labs?
Laurus Labs did better: Torrent Pharmaceuticals returned +32.0% and Laurus Labs returned +143.3% over one year.
Is Torrent Pharmaceuticals or Laurus Labs a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Torrent Pharmaceuticals scores 7/10 and Laurus Labs scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.